医薬品リファレンス
Amivantamab
Amivantamab is a medicine in the class oncology. It is used for non-small cell lung cancer.
- 薬効分類: Oncology
- 効能・効果: non-small cell lung cancer
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01FX18
- 一般的な剤形
- 注射剤
- 一般的な規格
- 350 mg
- 既知の相互作用
- 1 (中等度: 1)
- 商品名
- 2
- 国・市場
- 2
何に使われるか
作用のしくみ
Bispecific antibody that binds the extracellular domains of EGFR and MET, disrupting EGFR and MET signaling by blocking ligand binding or causing receptor degradation.
成人の通常用量（添付文書の要約）
NSCLC, with lazertinib or as single agent, under 80 kg: 1,050 mg IV weekly for Weeks 1-5 (split infusion on Day 1 and Day 2 of Week 1), no dose Week 6, then every 2 weeks from Week 7; until progression or unacceptable toxicity.
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm based on its mechanism (EGFR and MET blockade); no human data. Antibodies cross the placenta. Confirm pregnancy status before starting; use effective contraception during treatment and for 3 months after the last dose.
- 授乳
- Unsafe No data on milk levels or infant effects. Advise not to breastfeed during treatment and for 3 months after the last dose.
報告されている副作用
- Rash
- Infusion-related reaction
- Nail toxicity
- Musculoskeletal pain
- Stomatitis
- Fatigue
注意が必要な方
- Infusion-related reactions including anaphylaxis: premedicate, interrupt infusion at first sign, reduce rate or discontinue; permanently discontinue for anaphylaxis.
- Severe and fatal ILD/pneumonitis: withhold if suspected, permanently discontinue if confirmed.
- Serious and fatal VTE with lazertinib: give prophylactic anticoagulation for first four months; vitamin K antagonists not recommended.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (1)
- Amivantamab + Lazertinib Moderate
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Amivantamabの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
- IV preparation and dilution
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Amivantamab used for?
Amivantamab is a medicine in the class oncology. It is used for Non-small cell lung cancer.
What side effects have been reported with Amivantamab?
Rash, Infusion-related reaction, Nail toxicity, Musculoskeletal pain, Stomatitis, Fatigue.
Can Amivantamab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm based on its mechanism (EGFR and MET blockade); no human data. Antibodies cross the placenta. Confirm pregnancy status before starting; use effective contraception during treatment and for 3 months after the last dose. Breastfeeding: Unsafe. No data on milk levels or infant effects. Advise not to breastfeed during treatment and for 3 months after the last dose.
What does Amivantamab interact with?
MediHelp lists 1 known interactions for Amivantamab. Moderate: 1. The most serious include Lazertinib.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
